Skip to Main Content

Author Details

Jake Conway
2017
17
12
PMIDPaper TitleJournal TitlePublished Year
36993558Analysis of evolutionary dynamics and clonal architecture in prostate cancer.bioRxiv2023
37075704Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH.Cell Rep Med2023
34953602Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.Eur Urol2022
36075011Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer.JCO Precis Oncol2022
35121878Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology.Nat Cancer2021
33589424Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade.Cancer Discov2021
34099491Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival.Cancer Res2021
33257427Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.Clin Cancer Res2021
34496240Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer.Cell Rep2021
34548479Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.Nat Commun2021
32561875Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Nat Med2020
33201204Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma.JAMA2020
32923847Next-Generation Sequencing and the Clinical Oncology Workflow: Data Challenges, Proposed Solutions, and a Call to Action.JCO Precis Oncol2019
31792460Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Nat Med2019
29937226LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.Cell2018
30497521Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine.Genome Med2018
28645171UpSetR: an R package for the visualization of intersecting sets and their properties.Bioinformatics2017
  • 1 - 17 of 17

Recommended Authors

Collaborators

Dana-Farber Cancer Institute
Co-authored papers 13
Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 5
Co-authored papers 3
Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 3
Broad Institute of Harvard and MIT
Co-authored papers 2
Co-authored papers 2
Dana-Farber Cancer Institute
Co-authored papers 2
Broad Institute of MIT and Harvard
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Dana-Farber Cancer Institute
Co-authored papers 2
Broad Institute of Massachusetts Institute of Technology and Harvard
Co-authored papers 1
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 1
Cancer Science Institute of Singapore, National University of Singapore
Co-authored papers 1
National Cancer Institute
Co-authored papers 1
Inc.Foster CityCA.
Co-authored papers 1
Co-authored papers 1
Broad Institute of MIT and Harvard
Co-authored papers 1
Dana-Farber Cancer Institute
Co-authored papers 1
Dana-Farber Cancer Institute
Co-authored papers 1
Vanderbilt University Medical Center
Co-authored papers 1
Dana-Farber Cancer Institute
Co-authored papers 1
Broad Institute of Harvard and MIT
Co-authored papers 1
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 1
Beth Israel Deaconess Medical Center, Harvard Medical School
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Stanford University Medical Center
Co-authored papers 1
Anhui Medical University
Co-authored papers 1